Two separate 2020 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines provide recommendations on insulin and glucose for acute hyperkalemia. The acute hyperkalemia in the emergency department guidance states that 25-50 g of intravenous glucose should be administered with insulin; although studies cited in the guidance found similar potassium lowering with 5 versus 10 units of insulin and 10 versus 20 units, the guidance does not specify different glucose doses for these insulin regimens. It also notes that insulin may be administered without additional glucose when blood glucose is >200 mg/dL. Separately, the potassium homeostasis and management of dyskalemia in kidney diseases report suggests intravenous insulin and glucose, and notes that 5 units of regular insulin appears as effective as 10 units for lowering potassium, although evidence is limited, and presents a regimen of 5 units of intravenous regular insulin plus 25 g of glucose (50 mL of 50% glucose); neither publication provides a specific recommendation to adjust the glucose dose according to the insulin dose. [1], [2]
A 2023 clinical review summarized available evidence and provided key clinical recommendations for the evaluation and management of potassium disorders, including acute hyperkalemia. For acute hyperkalemia, the treatment algorithm includes 25 g of glucose (50 mL of D50W) administered with a 10-unit IV regular insulin bolus. If initial blood glucose is <100 mg/dL, the glucose dose is increased to 50 g (100 mL of D50W); glucose administration may not be necessary if initial blood glucose is >200 mg/dL. An additional 25 g of glucose is administered if serum glucose subsequently falls below 70 mg/dL. The review does not discuss dextrose dose adjustment in relation to the amount of insulin administered. [3]
Regarding insulin regimens for the management of emergency hyperkalemia, a 2016 systematic review evaluated 11 included studies reporting insulin doses, methods of administration, and corresponding glucose doses. Glucose doses varied from 25 to 60 g, with 25 g used in 6 studies; across the review, hypoglycemia occurred in 18% of patients and was most frequent in studies administering 25 g of glucose. Among studies using approximately 20 units of insulin, hypoglycemia occurred in 50% of patients when only 25 g of glucose was administered, compared with no reported hypoglycemia when 40 or 60 g was administered; among studies using 10 units of insulin, the fewest hypoglycemic events were observed with 50 g of glucose. Based on these findings, the authors suggested 50 g of glucose with 10 units of insulin and 60 g with 20 units of insulin, with frequent plasma glucose monitoring. [4]
Another 2019 narrative review evaluated insulin and dextrose dosing for acute hyperkalemia and reported that most references recommend 10 to 20 units of insulin with 25 to 50 g of dextrose for severe hyperkalemia. Although 25 g of dextrose with 10 units of IV insulin is commonly used, the authors noted that this regimen may provide insufficient glycemic coverage and suggested 50 g of dextrose or a prolonged dextrose infusion, particularly in patients at increased risk for hypoglycemia. Lower insulin doses of 5 units or 0.1 units/kg demonstrated generally similar potassium reductions to 10 units and may reduce hypoglycemia risk; however, the review did not recommend a specific dextrose dose adjustment according to the insulin dose. Blood glucose monitoring was recommended hourly for at least 4 to 6 hours following insulin administration. [5]
In a 2014 editorial commentary, insulin-dextrose regimens for acute hyperkalemia and strategies to reduce insulin-associated hypoglycemia in patients with end-stage renal disease (ESRD) were discussed. The authors noted substantial variation in published regimens, with insulin doses ranging from 5 to 10 units and dextrose doses from 25 to 60 g. Although 10 units of IV insulin with 25 g of dextrose was described as an effective regimen, clinically significant hypoglycemia remained a concern. The authors described their institutional protocol of 25 g of dextrose administered immediately before weight-based IV insulin (0.1 units/kg), followed by 250 mL of D10W infused over 2 hours, with blood glucose measured at baseline and 1, 2, and 3 hours after treatment. They noted limited data suggesting that administration of dextrose before insulin is effective and safe and reported that hypoglycemia at their institution decreased from approximately 20% to <5% after implementation of this protocol. [6]
A 2023 invited review on acute hyperkalemia states that rapid-acting insulin is usually administered as a 10-unit IV push, with dextrose administered simultaneously to prevent hypoglycemia. The review describes a study in which 25 g and 50 g of IV dextrose were compared with 10 units of IV insulin; hypoglycemia rates did not differ significantly at 60 minutes, although 50 g produced more transient hyperglycemia and appeared preferable in patients with risk factors for hypoglycemia. It also reports that reducing insulin from 10 units to 5 units while administering 25 g of dextrose did not protect against hypoglycemia, whereas weight-based insulin dosing (0.1 units/kg; maximum, 10 units) with 50 g of dextrose significantly reduced hypoglycemia compared with a fixed 10-unit insulin dose. The review does not specify that dextrose should be administered before insulin or recommend adjusting the dextrose dose proportionally according to the insulin dose. [7]
A 2022 scoping review of 62 studies evaluating insulin therapy for hyperkalemia reported that the most common regimen was 10 units of intravenous insulin administered with 25 g of dextrose, and the median dextrose dose across treatment arms was 25 g (interquartile range [IQR] 25 to 40 g). The prevalence of hypoglycemia did not differ between dextrose doses of ≤25 g and >25 g or according to whether dextrose was administered before, with, or after insulin. However, hypoglycemia occurred less frequently with continuous dextrose infusion than with bolus administration (3.3% vs 19.5%; p= 0.02). The review did not establish a specific dextrose dose adjustment based on the insulin dose and concluded that randomized trials are needed to identify the optimal insulin-dextrose regimen. [8]
Finally, a 2026 systematic review included 16 studies evaluating insulin and dextrose strategies for acute hyperkalemia, with insulin doses generally ranging from 5 to 10 units intravenously. Dextrose dosing varied across studies, most commonly 25 g or 50 g, with approximately half of the included studies supporting 25 g of dextrose with 10 units of insulin; three studies supported 50 g, with some evidence suggesting a lower risk of hypoglycemia compared with 25 g. The review noted that higher insulin doses and lower dextrose doses were associated with greater hypoglycemia risk, and suggested that lower insulin doses combined with higher dextrose doses may reduce this risk; however, the included studies used variable regimens and did not establish a specific dextrose dose that should accompany each insulin dose. Overall, the authors identified 25 g of dextrose as the most commonly reported dose, but emphasized the lack of consensus and need for prospective studies to establish standardized insulin and dextrose regimens. [9]